Antiretroviral therapy for HIV-associated tuberculosis

Asian Biomedicine

Volumn 3, Issue 1, 2009, Pages 73-87

  Avihingsanona, Anchalee ^a   Hemachandraa, Atchariya ^a   Van De Lugta, Jasper ^a,b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b International Antiviral Therapy Evaluation Center   (Netherlands)

Author keywords

Antiretroviral therapy; HIV associated TB; Rifampin based antiTB

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450; DELAVIRDINE; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANEMIA; ANTIVIRAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG COST; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC DISORDER; MORBIDITY; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; RADIODIAGNOSIS; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 70349339120     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Van der Lugt J, Avihingsanon A. Clinical pharmacology and pharmacokinetics of antiretrovirals in Asia. Asian Biomed. 2009; 3:51-60.
2. World Health Organization: Global report 2008. Available at :http://www.who.int/tb/publications/ global-report/2008. Accessed 17 November 2008.
3. Goldfeld A, Ellner JJ. Pathogenesis and management of HIV/TB co-infection in Asia. Tuberculosis (Edinb). 2007; 87(SUPPL. 1):S26-30.
4. World Health Organization: Proceedings of the WHO HIV/TB conference for the Mekong Sub-region HCMC, Viet Nam, October 10-14,2004. www.un.org.vn/ who/docs/mekonghivtb/proceedings. Accessed Nov 17, 2008.
5. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999;340:367-373
6. Aaron L, Saadoun D, Calatroni I, Launay O, Memain N, Vincent V, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect. 2004;10:388-398
7. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995; 151:129-135
8. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148:1292-1297
9. Garrait V, Cadranel J, Esvant H, Herry I, Morinet P, Mayaud C, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol. 1997;159: 2824-2830
10. Fee MJ, Oo MM, Gabayan AE, Radin DR, Barnes PF. Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1995; 20:938-944
11. Dube MP, Holtom PD, Larsen RA. Tuberculous meningitis in patients with and without human immunodeficiency virus infection. Am J Med. 1992; 93:520-524
12. Treating Opportunistic Infections Among HIVInfected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR, 2004. 2004; 53(RR-15): 1-112.
13. Perlman DC, el-Sadr WM, Nelson ET, Matts JP, Telzak EE, Salomon N, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1997;25:242-246
14. Smith RL, Yew K, Berkowitz KA, Aranda CP. Factors affecting the yield of acid-fast sputum smears in patients with HIV and tuberculosis. Chest. 1994;106: 684-686
15. DHHS. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected A dults and Adolescents (18June2008). Available at: www.aidsinfonihorg. 2008; Accessed 18 November 2008.
16. Bouza E, Diaz-Lopez MD, Moreno S, Bernaldo de Quiros JC, Vicente T, Berenguer J. Mycobacterium tuberculosis bacteremia in patients with and without human immunodeficiency virus infection. Arch Intern Med. 1993;153:496-500.
17. el-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, et al. Evaluation of an intensive intermittent-induction regimen and duration of shortcourse treatment for human immunodeficiency virusrelated pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998;26:1148-1158
18. Kassim S, Sassan-Morokro M, Ackah A, Abouya LY, Digbeu H, Yesso G, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS. 1995;9:1185-1191
19. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis. 2001; 32:623-632
20. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007;175:1199-1206
21. Lopez-Cortes LF, Marin-Niebla A, Lopez-Cortes LE, Villanego I, Rodriguez-Diez M, Pascual-Carrasco R. Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients. Int J Tuberc Lung Dis. 2005;9:1385-1390
22. CDC, American Thoracic Society and Infectious Diseases Society of America :Treatment of tuberculosis. MMWR Recomm Rep. 2003; 52(RR-11):1-77.
23. Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med. 2005;6(SUPPL. 2):62-83.
24. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741-1751
25. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med. 2006;173:350-356
26. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutinbased regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41:83-91.
27. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353:1843-1847
28. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364:1244-1251
29. Harries AD, Hargreaves NJ, Kemp J, Jindani A, Enarson DA, Maher D, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet. 2001;357:1519-1523 (Pubitemid 32488877)
30. Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL, et al. Comparison of intermittent ethambutol with rifampicin-based regimens in HIVinfected adults with PTB, Kampala. Int J Tuberc Lung Dis. 2006;10:39-44.
31. Johnson JL, Okwera A, Vjecha MJ, Byekwaso F, Nakibali J, Nyole S, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:446-453 (Pubitemid 127509629)
32. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996; 22 (SUPPL. 1):S15-21; discussion S-2.
33. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40: 327-341
34. Weber A, Kaplan M, Chughtai SA, Cohn LA, Smith AL, Unadkat JD. CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. Biopharm Drug Dispos. 2001;22:157-168
35. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126-136
36. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004; 38:731-736
37. Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995;76:210-218
38. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis. 1996; 22 (SUPPL. 1):S50-4.
39. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481-1491
40. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, Sitti W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2007;13:1001-1007
41. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIVinfected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.
42. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (3 November 2008). Available at: www.aidsinfo.nih.org 2008; Accessed 18 November 2008.
43. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-992
44. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon- Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681-690
45. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28: 450-453
46. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20:131-132
47. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005;19: 1481-1486
48. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naïve patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr. 2004;37:1166-1169
49. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, et al. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother. 2006;58:1017-1023
50. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. 2005;19: 1541-1543
51. CDC. Updated Guidelines for the Manageing Drug Interactions in the Treatment of HIV-Related Tuberculosis. Updated December 2007. Available at: http://www.cdc.gov/tb/TB-HIV-Drugs/default.html.
52. Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr. 2006;42:36-41.
53. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005;10:937-943
54. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, et l. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006;43:253-255
55. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13: 529-536
56. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007;44:141-144 (Pubitemid 44969000)
57. Manosuthi W, Tantanathip P, Prasithisirikul W, Likanonsakul S, Sungkanuparph S. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior coadministration of rifampicin: a 144-week prospective study. BMC Infect Dis. 2008;8:136.
58. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapineand efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530-539
59. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008;9: 294-299
60. Manosuthi WSS, Lueangniyomkul A, Mankatitham W, Tansuphaswadikul S, Prasithsirikul W, et al. A randomized control trial of two non-nucleoside reverse transcriptase inhibitor-based regimens in HIV- infected patients receiving rifampicin. IDSA/ ICCAC October 25-28, 2008 Washington DC, USA abstract H-1237.
61. Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, et al. Effect of rifampicin- based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIVassociated tuberculosis. J Antimicrob Chemother. 2008;61:389-393
62. Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis. 2004;38:426-429
63. La Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004;48: 1553-1560
64. Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother. 2007;59:690-697
65. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3336-3342
66. US Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. 2004. Available at http:// www.cdc.gov/nchstp/tb/TB-HIV-Drugs/PDF/tbhiv. pdf. 2004.
67. Ribera E, Azuaje C, Lopez RM, Domingo P, Soriano A, Pou L, et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J Acquir Immune Defic Syndr. 2005;40:317-323
68. Losso MH, Lourtau LD, Toibaro JJ, Saenz C, Gonzalez C. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Antivir Ther. 2004;9:1031-1033
69. Roche issues drug interaction warning. AIDS Alert. 2005;20:48.
70. Nijland HM, L'Homme R F, Rongen GA, van Uden P, van Crevel R, Boeree MJ, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS. 2008;22:931-935
71. Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virusinfected patients with tuberculosis. Clin Infect Dis. 2000;30:779-783
72. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, 3rd, et al. Triple- nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861
73. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18: 1615-1627
74. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIVinfected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006;53:357-363
75. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosisassociated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-341
76. Shelburne SA, 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213-227.